AML Classified Into 16 Epigenomic Subgroups

Researchers have developed an ATAC-seq-based approach to classify acute myeloid leukaemia (AML) into 16 distinct epigenomic subgroups. This classification provides significant insights into the role of non-genetic mechanisms in determining the pathogenesis, clinical behaviour, and drug sensitivity of AML. The findings, published online on July 8, 2026, in Nature, highlight the complex epigenetic landscape of the disease.

The study utilized ATAC-seq (Assay for Transposase-Accessible Chromatin using sequencing) to map regions of open chromatin, which are indicative of active gene regulatory elements. By analyzing these patterns across a cohort of AML patients, the researchers were able to identify unique epigenetic signatures that define different subgroups. This granular level of classification moves beyond traditional genetic markers to encompass the dynamic epigenetic alterations that contribute to AML's heterogeneity.

Understanding these epigenomic subgroups is crucial for developing more targeted and effective treatment strategies. The research suggests that variations in chromatin accessibility and epigenetic modifications can significantly influence how a patient's leukaemia responds to various therapies. This opens avenues for personalized medicine approaches, where treatments could be tailored based on an individual's specific epigenomic profile.

The implications of this research extend to predicting disease progression and relapse risk. By identifying distinct epigenomic states, clinicians may be better equipped to anticipate the clinical trajectory of AML in individual patients. This enhanced predictive capability, derived from a deeper understanding of epigenetic heterogeneity, could lead to earlier interventions and improved patient outcomes in the fight against acute myeloid leukaemia.